Literature DB >> 27635938

Prevalence and predictors of long corrected QT interval in HIV-positive patients: a multicenter study.

Sebastiano Gili1, Massimo Mancone, Flavia Ballocca, Walter Grosso Marra, Andrea Calcagno, Gabriella D'Ettorre, Margherita Cannillo, Fabrizio D'Ascenzo, Giancarlo Orofino, Laura Marruncheddu, Enrica Lonni, Alessandra Cinque, Francesco Vullo, Giancarlo Ceccarelli, Ilaria Vilardi, Gennaro Sardella, Vincenzo Vullo, Claudio Moretti, Francesco Fedele, Stefano Bonora, Fiorenzo Gaita.   

Abstract

AIMS: HIV and highly active antiretroviral therapy (HAART) may affect cardiac conduction, and a higher incidence of sudden death has been recognized in HIV-positive patients. Nevertheless, predictors of prolonged corrected QT interval (cQT) have been poorly described. The aim of the study was to investigate the prevalence and predictors of long cQT in a cohort of HIV-positive patients.
METHODS: Consecutive HIV-positive patients followed in a primary prevention clinic at two Italian institutions were retrospectively enrolled. A 12-lead ECG was recorded in all patients; main clinical features were collected. Prevalence of long cQT (defined as cQT >470 ms in women and >450 ms in men) was the primary end-point. Secondary end-points were the identification of predictors of cQT prolongation, and the association between HAART and HIV-related features with long cQT.
RESULTS: Three hundred and fifty-one HIV-positive patients were included, 26 (7.4%) with long cQT. Mean age was higher among those with long cQT (51.6 vs. 57.6 years; P = 0.007). A higher prevalence of long cQT was reported for patients with a CD4+ cell count below 200 cells/μl at the moment of ECG (60 vs. 24.2%; P = 0.002) and with a nadir of CD4+ cell count below 200 cells/μl (91.3 vs. 58.6%; P = 0.001). At multivariate analysis, only the nadir of CD4+ cell count below 200 cells/μl consistently related to the presence of long cQT (odds ratio 5.8, 95% confidence interval 1.3-26.4).
CONCLUSION: A low CD4+ cell count is associated with long cQT independently from HAART in HIV-positive patients and may be useful to correctly stratify arrhythmic risk in these patients.

Entities:  

Mesh:

Year:  2017        PMID: 27635938     DOI: 10.2459/JCM.0000000000000436

Source DB:  PubMed          Journal:  J Cardiovasc Med (Hagerstown)        ISSN: 1558-2027            Impact factor:   2.160


  6 in total

1.  Prolongation of the QTc interval in HIV-infected individuals compared to the general population.

Authors:  Nico Reinsch; Marina Arendt; Marie Henrike Geisel; Christina Schulze; Volker Holzendorf; Anna Warnke; Till Neumann; Norbert H Brockmeyer; Dirk Schadendorf; Lewin Eisele; Raimund Erbel; Susanne Moebus; Karl-Heinz Jöckel; Stefan Esser
Journal:  Infection       Date:  2017-08-03       Impact factor: 3.553

Review 2.  Safety implications of combined antiretroviral and anti-tuberculosis drugs.

Authors:  Maddalena Cerrone; Margherita Bracchi; Sean Wasserman; Anton Pozniak; Graeme Meintjes; Karen Cohen; Robert J Wilkinson
Journal:  Expert Opin Drug Saf       Date:  2019-12-06       Impact factor: 4.250

3.  Predictors of electrocardiographic QT interval prolongation in men with HIV.

Authors:  Katherine C Wu; Long Zhang; Sabina A Haberlen; Hiroshi Ashikaga; Todd T Brown; Matthew J Budoff; Gypsyamber D'Souza; Lawrence A Kingsley; Frank J Palella; Joseph B Margolick; Otoniel Martínez-Maza; Elsayed Z Soliman; Wendy S Post
Journal:  Heart       Date:  2018-10-26       Impact factor: 5.994

Review 4.  The role of HIV Tat protein in HIV-related cardiovascular diseases.

Authors:  Yanan Jiang; Lu Chai; Moyondafoluwa Blessing Fasae; Yunlong Bai
Journal:  J Transl Med       Date:  2018-05-08       Impact factor: 5.531

5.  Prolonged QTc in HIV-Infected Patients: A Need for Routine ECG Screening.

Authors:  Merle Myerson; Emma Kaplan-Lewis; Eduard Poltavskiy; David Ferris; Heejung Bang
Journal:  J Int Assoc Provid AIDS Care       Date:  2019 Jan-Dec

6.  The Use of First Line Highly Active Anti-Retroviral Therapy (HAART) is Not Associated with Qtc Prolongation in HIV Patients.

Authors:  James Ogunmodede; Philip Kolo; Ibraheem Katibi; Ayodele Omotoso
Journal:  Ethiop J Health Sci       Date:  2017-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.